Peptide research protocols.

Retatrutide

GLP-1 / GIP / glucagon triple agonist

Start with

2 mg once weekly, subcutaneous.

Build up to

Increase by 2 mg every 4 weeks, up to a maximum of 12 mg once weekly if well tolerated.

Run for

6–12 months of continuous weekly dosing in long-term metabolic research.

Time off after

4–6 weeks washout before starting a new cycle.

Route & timing: Subcutaneous injection to abdomen, thigh or upper arm, same day each week. Maintain at least 4 weeks at each dose before escalation to assess tolerability.

For laboratory research use only. Not for human or animal consumption.

Tirzepatide

GLP-1 / GIP dual agonist

Start with

2.5 mg once weekly, subcutaneous.

Build up to

Increase by 2.5 mg every 4 weeks, up to 10–15 mg once weekly if tolerated.

Run for

6–12 months for chronic metabolic and body-weight research models.

Time off after

4–6 weeks washout.

Route & timing: Subcutaneous, same day each week; rotate injection sites.

For laboratory research use only. Not for human or animal consumption.

Semaglutide

GLP-1 agonist

Start with

0.25 mg once weekly, subcutaneous.

Build up to

Step up every 4 weeks (0.25 → 0.5 → 1.0 → 1.7 mg), with 2.4 mg once weekly as a typical maximum in intensive weight-loss models.

Run for

3–12 months in chronic metabolic research.

Time off after

4–6 weeks washout.

Route & timing: Subcutaneous, same weekday; use consistent timing relative to feeding in animal models.

For laboratory research use only. Not for human or animal consumption.

GLOW · 70 mg

BPC-157 + TB-500 + GHK-Cu

Single 70 mg vial combining BPC-157, TB-500 and GHK-Cu.

Start with

2–3 mg total blend per day, subcutaneous.

Build up to

Up to 5 mg per day in high-intensity tissue-repair models if tolerated.

Run for

4–8 weeks for injury-recovery or dermal-repair studies.

Time off after

2–4 weeks off before repeating a cycle.

Route & timing: Subcutaneous. For injury studies, inject near (not into) the affected area; for skin or hair studies, perilesional or systemic administration.

For laboratory research use only. Not for human or animal consumption.

KLOW · 80 mg

GLOW + KPV

80 mg vial containing BPC-157, TB-500, GHK-Cu and KPV.

Start with

2–3 mg per day, subcutaneous.

Build up to

Up to 5 mg per day where stronger anti-inflammatory exposure is desired.

Run for

4–8 weeks, aligned to the inflammatory or tissue-repair model.

Time off after

2–4 weeks off before re-starting.

Route & timing: Subcutaneous; rotate sites. For gut or autoimmune models, consider low-dose daily systemic administration.

For laboratory research use only. Not for human or animal consumption.

Melanotan 2 (MT-II)

Pigmentation & photobiology research

Start with

250–500 mcg once daily to assess response.

Build up to

Increase by 250–500 mcg as needed up to around 1 mg daily in intensive pigmentation studies.

Run for

2–4 weeks loading, then 1 mg once weekly as a typical maintenance exposure in long-term models.

Time off after

4 weeks off between long maintenance phases if modelling on / off exposure.

Route & timing: Subcutaneous; often dosed in the evening to track photobiological changes separate from UV exposure.

For laboratory research use only. Not for human or animal consumption.

GHK-Cu (systemic)

Copper-binding tripeptide

Start with

1–2 mg per day, subcutaneous.

Build up to

Up to 3–5 mg per day in systemic anti-ageing or tissue-repair models.

Run for

4–6 weeks.

Time off after

2–4 weeks.

Route & timing: Subcutaneous or intradermal; for cosmetic research, local micro-injections or topical formulations are common.

For laboratory research use only. Not for human or animal consumption.

MOTS-C

Mitochondrial-derived peptide

Start with

5–10 mg, 2–3 times per week, subcutaneous.

Build up to

Up to 10–15 mg, 3 times per week in high-intensity metabolic or exercise-adaptation experiments.

Run for

4–12 weeks per cycle depending on the model (acute vs chronic metabolic stress).

Time off after

4 weeks off between longer cycles.

Route & timing: Subcutaneous; commonly administered pre-exercise or at a fixed time of day to standardise circadian influence.

For laboratory research use only. Not for human or animal consumption.

SS-31 (Elamipretide)

Mitochondrial-targeted antioxidant

Start with

1–2 mg once daily, subcutaneous or intraperitoneal in animal models.

Build up to

Up to 3–5 mg per day in models of high oxidative stress or organ-specific injury.

Run for

4–8 weeks, or shorter intensive courses (5–14 days) in acute-injury paradigms.

Time off after

At least equal time off as "on" for chronic protocols (e.g. 4 weeks on, 4 weeks off).

Route & timing: Subcutaneous or IV in appropriate lab settings; dose timing often aligned with, or just before, peak oxidative-stress periods in the protocol.

For laboratory research use only. Not for human or animal consumption.

Selank

Anxiolytic-pathway research peptide

Start with

250–300 mcg, 1–2 times per day.

Build up to

Up to 500–750 mcg, 2–3 times per day in intensive anxiolytic-pathway models.

Run for

4–8 weeks continuous dosing.

Time off after

2–4 weeks washout before repeating.

Route & timing: Intranasal micro-dosing is common in neuro models; subcutaneous is used in systemic designs.

For laboratory research use only. Not for human or animal consumption.

Semax

Cognitive-performance research peptide

Start with

250–300 mcg, 1–2 times per day.

Build up to

Up to 500–750 mcg, 2–3 times per day in cognitive-performance experiments.

Run for

4–8 weeks.

Time off after

2–4 weeks.

Route & timing: Often administered intranasally in divided doses (e.g. morning and early afternoon) in learning / memory paradigms.

For laboratory research use only. Not for human or animal consumption.

KPV

Anti-inflammatory tripeptide

Start with

250–500 mcg once or twice daily.

Build up to

Up to 1 mg, 1–2 times daily in high-inflammation models.

Run for

4–8 weeks depending on gut, dermal or autoimmune model duration.

Time off after

2–4 weeks.

Route & timing: Subcutaneous. For gut-focused work, some protocols explore oral or rectal formulations, but the standard card route is subcutaneous.

For laboratory research use only. Not for human or animal consumption.

Glutathione

Master antioxidant tripeptide

Start with

200–400 mg, 2–3 times per week.

Build up to

Up to 600–1200 mg, 2–3 times per week when modelling aggressive antioxidant support.

Run for

4–12 weeks.

Time off after

4 weeks off, or switch to lower maintenance dosing (e.g. weekly) in long-term designs.

Route & timing: Parenteral administration (IM / IV) in appropriate lab settings.

For laboratory research use only. Not for human or animal consumption.

NAD+

Cellular energy & sirtuin coenzyme

Start with

250–500 mg once weekly IV or slow IM in longevity-style models.

Build up to

Up to 500–1000 mg, 1–2 times per week in high-dose protocols.

Run for

4–12 weeks.

Time off after

4 weeks before repeating a high-dose course.

Route & timing: Typically IV infusion over 60–180 minutes in human research; IM or SC exposure is used in some animal models.

For laboratory research use only. Not for human or animal consumption.

CJC-1295 NO-DAC + Ipamorelin

5 mg + 5 mg pulsatile-GH blend

Start with

100 mcg CJC-1295 + 100 mcg Ipamorelin, once daily.

Build up to

200–300 mcg of each peptide, 1–3 times per day (common: bedtime only, or morning + bedtime).

Run for

8–12 weeks continuous pulsatile dosing.

Time off after

4 weeks off between long GH-axis cycles.

Route & timing: Subcutaneous on an empty stomach; often dosed pre-sleep to align with endogenous GH pulses.

For laboratory research use only. Not for human or animal consumption.

Tesamorelin · 10 mg

GHRH analogue · visceral-fat research

Start with

1 mg once daily, subcutaneous (split from 10 mg vial).

Build up to

Up to 2 mg daily in higher-dose visceral-fat models.

Run for

3–6 months in body-composition research.

Time off after

4–8 weeks before starting a new long course.

Route & timing: Subcutaneous, typically in the abdomen at a consistent time of day.

For laboratory research use only. Not for human or animal consumption.

BPC-157

Body protection compound

Start with

250–500 mcg once or twice daily.

Build up to

Up to 1 mg twice daily in intensive tendon, ligament or gut models.

Run for

4–6 weeks for localised injury; up to 12 weeks in chronic-injury paradigms.

Time off after

2–4 weeks off between longer cycles.

Route & timing: Subcutaneous near the injury site or systemic; oral or intragastric routes are also described for gut-specific work.

For laboratory research use only. Not for human or animal consumption.

TB-500

Thymosin beta-4 fragment

Start with

2–5 mg twice weekly for 4–6 weeks (loading phase).

Build up to

Up to 5 mg, 2–3 times weekly in heavy-injury models during loading.

Run for

4–6 weeks loading, followed by 2–5 mg once weekly as maintenance if required.

Time off after

4–6 weeks off between long maintenance runs.

Route & timing: Subcutaneous; may be injected regionally around the injured tissue.

For laboratory research use only. Not for human or animal consumption.

Thymosin Alpha-1

Immune-modulation research peptide

Start with

0.8–1.6 mg, 2–3 times per week.

Build up to

Up to 3–4 mg, 2–3 times per week in intensive immune-modulation studies.

Run for

4–12 weeks.

Time off after

At least 4 weeks between long courses.

Route & timing: Subcutaneous; often split across two weekly injections (e.g. Monday and Thursday).

For laboratory research use only. Not for human or animal consumption.